Harmony Biosciences
HRMY
About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Employees: 268
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
366% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $2.26M
84% more repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 68
33% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 30
3% more funds holding
Funds holding: 267 [Q1] → 275 (+8) [Q2]
1.73% more ownership
Funds ownership: 87.44% [Q1] → 89.17% (+1.73%) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
3% less capital invested
Capital invested by funds: $1.66B [Q1] → $1.62B (-$44.2M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
Truist Securities
Danielle Brill
|
$48
|
Buy
Initiated
|
21 Jul 2025 |
|
Deutsche Bank
David Hoang
|
$55
|
Buy
Maintained
|
10 Jul 2025 |
Financial journalist opinion
Based on 5 articles about HRMY published over the past 30 days
